Finding advances search for cure other than liver transplantation
A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.
The investigators say the findings, reported ahead of print in the March 3 early view edition of Hepatology, advance the search for a potential cure for the thousands of patients worldwide living with these incurable diseases. At present, there is little effective treatment and no cure other than liver transplantation, which carries its own risks and often fails.
“Our findings demonstrate that the damaging effects of liver cirrhosis in laboratory rats can be effectively treated, and perhaps even reversed, using a protein therapeutic that has been modified to enhance its activity through site-specific conjugation of a polymer that greatly enhances its residence time in the body,” says senior author Justin Hanes, Ph.D., director of the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins. “This approach has tremendous potential to help people with this devastating condition and may also be helpful to the millions of patients with other diseases where fibrosis plays an important role.”
Liver fibrosis and its more severe form, cirrhosis, are caused by scar tissue that forms in the liver that is usually induced by chronic alcohol abuse, infections and autoimmune diseases. The progressive stiffening of the liver, a hallmark of the disorders, occurs when a type of liver cell known as the hepatic stellate cell is “activated” and overproduces the stringy network of proteins called the extracellular matrix that binds cells together.
Being able to turn cirrhosis around, especially in its late stages, would be a great boon, says Seulki Lee, Ph.D., assistant professor in the Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. “That’s because liver fibrosis and cirrhosis can be asymptomatic for decades,” Lee says. “Many patients only seek treatment when their disease becomes very advanced, at which point liver transplant is their only option.”
Lee cautions, however, that his team’s work is years from any possible application to patients.
Scientists have known for more than a decade that a protein called tumor necrosis factor-related apoptosis-inducing ligand — TRAIL, for short — can specifically kill activated hepatic stellate cells that overproduce the extracellular matrix, sparing healthy cells in the liver. However, Lee explains, TRAIL has thus far proven unsuccessful for clinical use because in animal studies, enzymes in the bloodstream quickly degrade it before it has time to work.
Seeking a way to extend TRAIL’s half-life, or the time that it remains intact in the bloodstream, Lee and his colleagues coated TRAIL with polyethylene glycol (PEG), a synthetic polymer that’s widely used as a preservative, lubricant and ingredient in skin creams, and is already being used to extend the bloodstream life of a handful of drugs that treat neutropenia, hemophilia and rheumatoid arthritis.
Lee says initial experiments showed that this “PEGylated” TRAIL had a half-life of between eight and nine hours in monkeys, compared to less than 30 minutes for the unmodified protein. When the scientists intravenously dosed rats that had liver fibrosis with the modified TRAIL for 10 days, the animals’ activated hepatic stellate cells died off. By fighting these bad cells, signs of fibrosis began to diminish. Further investigation showed that multiple genes associated with fibrosis had reduced activity, and the proteins produced by these genes faded away.
Findings were similar in rats with advanced cirrhosis, Lee says. Additionally, when the researchers examined the rodents’ liver tissue under a microscope, they found that animals treated with PEGylated TRAIL had fewer deposits of collagen and other extracellular matrix proteins, offering some evidence that the disease had actually been reversed.
Further experiments showed that PEGylated TRAIL selectively killed human-activated hepatic stellate cells growing in petri dishes while leaving normal liver cells unharmed, suggesting that findings in these animal models could apply to damaged human livers with limited toxicity concerns.
Lee says the research team hopes to develop PEGylated TRAIL for clinical trials in human patients in the next two years. He adds that some preliminary data suggest that the modified protein could also treat other fibrotic diseases as well, such as pancreatic or lung fibrosis, which also have no effective treatment.
“Eventually,” Lee says, “we might be able to develop PEGylated TRAIL into a universal anti-fibrotic agent that can treat many different conditions.”
Learn more:Â Modified protein reverses cirrhosis in lab rats
The Latest on: Protein therapeutic
[google_news title=”” keyword=”Protein therapeutic” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Protein therapeutic
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcripton May 2, 2024 at 8:08 am
Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.37, expectations were $-0.11. Sarepta Therapeutics, Inc.
- Kelonia Therapeutics to Participate in Upcoming Scientific Conferenceson May 2, 2024 at 5:00 am
Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that ...
- Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officeron May 1, 2024 at 10:00 pm
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel ...
- Global Plant-Derived Proteins Market Expected to Reach US$ 184.3 Million by 2029on May 1, 2024 at 8:44 pm
The global plant-derived proteins market is witnessing an unprecedented surge, projected to reach a value of US$ 105 million by the end of 2022, and anticipated to soar past US$ 184.3 million by 2029.
- Tsetse fly protein provides anticoagulant with its own on-off switchon May 1, 2024 at 7:12 pm
A completely novel way to develop 'surpamolecules' for drug discovery could have application in immunotherapy as well as this breakthrough design for an anticoagulant with on-demand reversibility.
- Enlaza Therapeutics secures $100m in Series A fundingon May 1, 2024 at 6:09 am
E nlaza Therapeutics has raised $100m in a Series A financing round headed by the Life Sciences group of JP Morgan Asset Management’s private capital division.
- Invest In A Revolutionary Gene Therapy With CRISPR Therapeuticson April 30, 2024 at 10:25 am
CRISPR Therapeutics' Casgevy could generate significant shareholder value if proven to be successful. Learn why I am highly bullish on CRSP stock.
- Targeting protein interactions may boost antitumor immunity in breast canceron April 30, 2024 at 8:21 am
A multi-institutional team of investigators has discovered that targeting a specific protein interaction within immunosuppressive breast cancer cells may increase antitumor immune responses in ...
- CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Developmenton April 30, 2024 at 4:44 am
PRESS RELEASECHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical DevelopmentLONDON – 30 April 2024 ...
- Protein responsible for genetic inflammatory disease identifiedon April 29, 2024 at 10:47 am
A team of researchers led by Dr. Hirotsugu Oda at the University of Cologne's CECAD Cluster of Excellence for Aging Research has discovered the role a specific protein complex plays in certain forms ...
via Bing News